Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding

Stock Information for Tevogen Bio Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Tevogen Bio Holdings Inc.

Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest
CD8 Technology Signs Letter of Intent for Tevogen Bio's In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment
Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts
Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald
Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion
Tevogen Bio Announces 2025 Annual Meeting
Tevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production Facility
Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.